UBS Group’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.02M | Buy |
219,319
+39,578
| +22% | +$103K | ﹤0.01% | 5716 |
|
|
2026
Q1 | $501K | Buy |
179,741
+140,637
| +360% | +$428K | ﹤0.01% | 6084 |
|
|
2025
Q4 | $163K | Buy |
39,104
+7,590
| +24% | +$40K | ﹤0.01% | 6672 |
|
|
2025
Q3 | $133K | Sell |
31,514
-136,351
| -81% | -$513K | ﹤0.01% | 6927 |
|
|
2025
Q2 | $354K | Buy |
167,865
+115,621
| +221% | +$173K | ﹤0.01% | 6301 |
|
|
2025
Q1 | $63.7K | Buy |
52,244
+464
| +0.9% | +$651 | ﹤0.01% | 7394 |
|
|
2024
Q4 | $66.8K | Buy |
51,780
+37,448
| +261% | +$89.7K | ﹤0.01% | 7114 |
|
|
2024
Q3 | $39.4K | Buy |
14,332
+1,125
| +9% | +$2.76K | ﹤0.01% | 6972 |
|
|
2024
Q2 | $29.8K | Buy |
+13,207
| New | +$40.1K | ﹤0.01% | 7059 |
|
|
2024
Q1 | – | Sell |
-622
| Closed | -$1.03K | – | 9559 |
|
|
2023
Q4 | $1.03K | Buy |
+622
| New | +$1.21K | ﹤0.01% | 8425 |
|
|
2023
Q1 | – | Sell |
-5,561
| Closed | -$6.28K | – | 9851 |
|
|
2022
Q4 | $6.28K | Buy |
+5,561
| New | +$7.41K | ﹤0.01% | 9057 |
|
|
2022
Q3 | – | Sell |
-1,776
| Closed | -$2K | – | 10541 |
|
|
2022
Q2 | $2K | Buy |
+1,776
| New | +$2.55K | ﹤0.01% | 9554 |
|
|
2021
Q4 | – | Sell |
-1,988
| Closed | -$8K | – | 10406 |
|
|
2021
Q3 | $8K | Buy |
1,988
+988
| +99% | +$3.35K | ﹤0.01% | 8197 |
|
|
2021
Q2 | $3K | Sell |
1,000
-5,454
| -85% | -$19.4K | ﹤0.01% | 8801 |
|
|
2021
Q1 | $14K | Sell |
6,454
-17,114
| -73% | -$38.4K | ﹤0.01% | 7673 |
|
|
2020
Q4 | $53K | Buy |
23,568
+20,572
| +687% | +$54K | ﹤0.01% | 6133 |
|
|
2020
Q3 | $8K | Sell |
2,996
-9,405
| -76% | -$26.3K | ﹤0.01% | 7009 |
|
|
2020
Q2 | $38K | Sell |
12,401
-12,608
| -50% | -$31.7K | ﹤0.01% | 6095 |
|
|
2020
Q1 | $49K | Sell |
25,009
-26,310
| -51% | -$64K | ﹤0.01% | 5845 |
|
|
2019
Q4 | $147K | Buy |
51,319
+17,891
| +54% | +$62.2K | ﹤0.01% | 5792 |
|
|
2019
Q3 | $123K | Buy |
33,428
+15,348
| +85% | +$55.5K | ﹤0.01% | 5631 |
|
|
2019
Q2 | $75K | Buy |
18,080
+11,356
| +169% | +$49.2K | ﹤0.01% | 5593 |
|
|
2019
Q1 | $34K | Sell |
6,724
-2,382
| -26% | -$11.4K | ﹤0.01% | 5836 |
|
|
2018
Q4 | $31K | Buy |
9,106
+7,151
| +366% | +$34.2K | ﹤0.01% | 6463 |
|
|
2018
Q3 | $12K | Sell |
1,955
-5,246
| -73% | -$28.9K | ﹤0.01% | 7066 |
|
|
2018
Q2 | $46K | Buy |
7,201
+1,079
| +18% | +$5.25K | ﹤0.01% | 6036 |
|
|
2018
Q1 | $29K | Buy |
+6,122
| New | +$28.5K | ﹤0.01% | 6111 |
|
|
2017
Q4 | – | Sell |
-6,643
| Closed | -$14K | – | 7935 |
|
|
2017
Q3 | $14K | Buy |
6,643
+4,230
| +175% | +$8.38K | ﹤0.01% | 6698 |
|
|
2017
Q2 | $6K | Sell |
2,413
-1,292
| -35% | -$3.44K | ﹤0.01% | 7047 |
|
|
2017
Q1 | $9K | Buy |
3,705
+2,864
| +341% | +$4.32K | ﹤0.01% | 6673 |
|
|
2016
Q4 | $1K | Buy |
+841
| New | +$747 | ﹤0.01% | 7621 |
|
|
2016
Q3 | – | Sell |
-5,936
| Closed | -$9K | – | 7758 |
|
|
2016
Q2 | $9K | Buy |
5,936
+5,846
| +6,496% | +$8.57K | ﹤0.01% | 6834 |
|
|
2016
Q1 | $0 | Hold |
90
| – | – | ﹤0.01% | 7819 |
|
|
2015
Q4 | $0 | Sell |
90
-2,867
| -97% | -$6.57K | ﹤0.01% | 8427 |
|
|
2015
Q3 | $7K | Buy |
2,957
+845
| +40% | +$1.99K | ﹤0.01% | 7493 |
|
|
2015
Q2 | $6K | Buy |
2,112
+504
| +31% | +$1.52K | ﹤0.01% | 7784 |
|
|
2015
Q1 | $6K | Sell |
1,608
-1,906
| -54% | -$6.81K | ﹤0.01% | 8005 |
|
|
2014
Q4 | $12K | Buy |
+3,514
| New | +$15.5K | ﹤0.01% | 8220 |
|
Other funds holding GALT
WANY
UBS Group's GALT Position: Q2 2026 in Review
UBS Group increased its Galectin Therapeutics (GALT) stake by 22% in Q2 2026, buying an estimated $103K and bringing the position to 219,319 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5716.
UBS Group first reported a position in GALT in Q4 2014 and has held it in 38 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- UBS Group held 219,319 shares of Galectin Therapeutics worth $1.02M as of Q2 2026.
- UBS Group bought 39,578 Galectin Therapeutics shares in Q2 2026, an estimated $103K.
- Galectin Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5716 holding.
- UBS Group first reported a position in Galectin Therapeutics in Q4 2014 and has held it in 38 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.